WO2004066967B1 - Method and kit for reducing the symptoms of peripheral vascular disease - Google Patents

Method and kit for reducing the symptoms of peripheral vascular disease

Info

Publication number
WO2004066967B1
WO2004066967B1 PCT/US2004/000941 US2004000941W WO2004066967B1 WO 2004066967 B1 WO2004066967 B1 WO 2004066967B1 US 2004000941 W US2004000941 W US 2004000941W WO 2004066967 B1 WO2004066967 B1 WO 2004066967B1
Authority
WO
WIPO (PCT)
Prior art keywords
administration
pvd
progestin
topical application
kit
Prior art date
Application number
PCT/US2004/000941
Other languages
French (fr)
Other versions
WO2004066967A3 (en
WO2004066967A2 (en
Original Assignee
Dimera Inc
Hermsmeyer R Kent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimera Inc, Hermsmeyer R Kent filed Critical Dimera Inc
Priority to EP04702515A priority Critical patent/EP1594510A4/en
Priority to JP2006502824A priority patent/JP2006515890A/en
Publication of WO2004066967A2 publication Critical patent/WO2004066967A2/en
Publication of WO2004066967A3 publication Critical patent/WO2004066967A3/en
Publication of WO2004066967B1 publication Critical patent/WO2004066967B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for reducing the symptoms of peripheral vascular disease wherein a chemical agent that reduces peripheral vascular hyperreactivity in response to a stimulus for contraction of peripheral vascular musculature is administered to a subject in need thereof. Kits for administering the chemical agent to reduce the symptoms of peripheral vascular disease.

Claims

AMENDED CLAIMS
[Received by the International Bureau on 07 February 2005 (07.02.2005); original claims 1-39 replaced by amended claims 1-30 (5 pages)]
+ STATEMENT 1. A method or reducing the symptoms of peripheral vascular disease (PVD) comprising administering to a subject in need thereof an effective amount of a progestin, thereby reducing the incidence and/or the severity of symptoms of PVD.
2. The method of claim 1 wherein the PVD is selected from the group consisting of Raynaud's, intermittent claudication, thromboangiitis obliterans, and PVD secondary to diabetes, lupus, scleroderma, or atherosclerosis.
3. The method of claim 1 wherein the PVD is Raynaud's.
4. The method of claim 1 wherein the progestin is progesterone .
5. The method of claim 1 wherein the administration is oral .
6. The method of claim 1 wherein the administration is by topical application to the skin.
7. The method of claim 6 wherein the topical application is by a cream, lotion, gel, or ointment.
8. The method of claim 6 wherein the topical
29 administration is by a transdermal patch.
9. A method to decrease peripheral vascular muscle hyperreactivity comprising administering to a subject in need thereof an effective amount of a progestin.
10. The method of claim 9 wherein the progestin is progesterone.
11. The method of claim 9 wherein the administration is oral .
12. The method of claim 9 wherein the administration is by topical application to the skin.
13. The method of claim 12 wherein the topical application is by a cream, lotion, gel, or ointment.
14. The method of claim 12 wherein the topical administration is by a transdermal patch.
15. The method of claim 9 wherein the therapeutic agent is progesterone and the administration is by topical application to the skin.
16. A method to improve peripheral circulation by
30 reducing vascular muscle hyperreactivity comprising administering to a subject in need thereof an effective amount of a progestin.
17. The method of claim 16 wherein the subject is suffering from a peripheral vascular disease (PVD) .
18. The method of claim 17 wherein the PVD is selected from the group consisting of Raynaud's, intermittent claudication, thromboangiitis obliterans, and PVD secondary to diabetes, lupus, scleroderma, or atherosclerosis.
19. The method of claim 18 wherein the PVD is Raynaud's.
20. The method of claim 16 wherein the progestin is progesterone .
21. The method of claim 16 wherein the administration is oral .
22. The method of claim 16 wherein the administration is by topical application to the skin.
23. The method of claim 22 wherein the topical application is by a cream, lotion, gel, or ointment.
24. The method of claim 22 wherein the topical administration is by a transdermal patch.
25. The method of claim 16 wherein the therapeutic agent is progesterone and the administration is by topical application to the skin.
26. A kit for dispensing a pharmaceutical comprising: a package housing, a container, a pharmaceutical preparation in the container, which preparation contains a progestin, and instructions for administering an amount of the preparation which is effective in reducing the symptoms of peripheral vascular disease.
27. The kit of claim 26 wherein the progestin is progesterone .
28. The kit of claim 26 wherein the pharmaceutical preparation is a formulation for topical administration to the skin.
29. The kit of claim 28 wherein the preparation is a lotion, ointment, gel, or cream.
32
30. The kit of claim 28 wherein the pharmaceutical preparation is in the form of a transdermal patch.
33
PCT/US2004/000941 2003-01-21 2004-01-15 Method and kit for reducing the symptoms of peripheral vascular disease WO2004066967A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04702515A EP1594510A4 (en) 2003-01-21 2004-01-15 Method and kit for reducing the symptoms of peripheral vascular disease
JP2006502824A JP2006515890A (en) 2003-01-21 2004-01-15 Methods and kits for symptoms of peripheral vascular disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/348,570 US7572780B2 (en) 2003-01-21 2003-01-21 Method and kit for reducing the symptoms of peripheral vascular disease
US10/348,570 2003-01-21

Publications (3)

Publication Number Publication Date
WO2004066967A2 WO2004066967A2 (en) 2004-08-12
WO2004066967A3 WO2004066967A3 (en) 2005-03-03
WO2004066967B1 true WO2004066967B1 (en) 2005-04-14

Family

ID=32712580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000941 WO2004066967A2 (en) 2003-01-21 2004-01-15 Method and kit for reducing the symptoms of peripheral vascular disease

Country Status (4)

Country Link
US (3) US7572780B2 (en)
EP (1) EP1594510A4 (en)
JP (1) JP2006515890A (en)
WO (1) WO2004066967A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
EP2877184B1 (en) 2012-07-27 2019-09-04 Glia Llc Compositions and treatment for eye diseases and disorders
US9381231B2 (en) 2012-10-09 2016-07-05 University Of Florida Research Foundation, Inc. Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (en) 2014-05-22 2017-02-22 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies.
RU2016141135A (en) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. TRANSDERMAL CREAM
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408345A1 (en) * 1976-11-30 1979-06-08 Besins Jean Louis NEW COMPOSITION WITH ANTI-CONCEPTIONAL ACTION
DE3514724A1 (en) 1985-04-24 1986-10-30 Albin F. Dr. 4200 Oberhausen Jereb Ointment for the prevention and treatment of disorders of the eyes and skin
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4900734A (en) 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US5422119A (en) 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US4800734A (en) * 1987-11-02 1989-01-31 White Consolidated Industries, Inc. Room air conditioner
EP0399432B1 (en) 1989-05-25 1994-06-22 Takeda Chemical Industries, Ltd. Transdermal therapeutic composition
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
US5859001A (en) 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
EP0754701B1 (en) 1994-04-04 1998-08-12 Meiji Milk Products Company Limited Novel progesterone compound and use thereof
US5696123A (en) * 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists
US6613757B1 (en) 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
JPH08180574A (en) * 1994-12-28 1996-07-12 Teac Corp Disc unit
US5612051A (en) 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US5744463A (en) 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
IT1283102B1 (en) * 1996-06-06 1998-04-07 Permatec Nv THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES
US6228852B1 (en) 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
US6056972A (en) 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
US6440954B1 (en) 1997-04-18 2002-08-27 President And Fellows Of Harvard College Inhibition of vascular smooth muscle cell proliferation
EP0980384A1 (en) 1997-05-02 2000-02-23 American Home Products Corporation Pregnane 3,2o diol mono- and di-sulphates
US5998638A (en) 1997-05-02 1999-12-07 American Home Products Corporation Ester salt of 5α-pregn-16-en-3β-ol-20-one 3-sulfate
PT981349E (en) 1997-05-02 2003-01-31 Wyeth Corp PREGNAN-3-OL-20-ONAS
US5968918A (en) 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US5988918A (en) * 1998-04-24 1999-11-23 Johnson; Gary D. Flat folding writing instrument
AU2609401A (en) 1999-12-29 2001-07-09 Nicholas Kipshidze Apparatus and method for delivering compounds to a living organism
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
AU2003272378A1 (en) 2002-09-12 2004-04-30 X-Cell Medical, Inc. Apparatus and method for delivering compounds to a living organism

Also Published As

Publication number Publication date
US20040142913A1 (en) 2004-07-22
WO2004066967A3 (en) 2005-03-03
US20120232046A1 (en) 2012-09-13
US8182833B2 (en) 2012-05-22
EP1594510A4 (en) 2008-07-23
US20090275544A1 (en) 2009-11-05
JP2006515890A (en) 2006-06-08
EP1594510A2 (en) 2005-11-16
US7572780B2 (en) 2009-08-11
WO2004066967A2 (en) 2004-08-12
US8420111B2 (en) 2013-04-16

Similar Documents

Publication Publication Date Title
WO2004066967B1 (en) Method and kit for reducing the symptoms of peripheral vascular disease
US9387227B2 (en) Method for treatment of sores and lesions of the skin
CA2361407A1 (en) Pharmaceutical compositions
WO1996023490A9 (en) Formulations and methods for reducing skin irritation
EP0806947A1 (en) Formulations and methods for reducing skin irritation
WO2003028667A3 (en) Semisolid topical hormonal compositions and methods for treatment
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
JP2001354591A (en) Method for treating onychomycosis
WO2002069963A3 (en) Compositions comprising ferulic acid, caffeic acid, tannic acid or ellagic acid and their use for the preparation of a medicament for the treatment of dermatological disorders
WO2004087141B1 (en) Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases
WO2021237193A1 (en) Use of nad+ precursors, sting inhibitors, and fxr agonists for inhibiting sars-cov-2 (covid-19)-induced cytokine release
Trüeb Therapies for childhood psoriasis
Hendricks et al. Contact dermatitis due to nitroglycerin ointment
AU2003294027B2 (en) Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate
WO2006036484A2 (en) Treatment of dermatitis with dehydroepiandrosterone-glucocorticoid combinations
US6096738A (en) Method for treatment of headache
JPS6356206B2 (en)
CA2472309A1 (en) Multiple dose aromatase inhibitor for treating infertility
JPH09502737A (en) New treatments for topical treatment of psoriasis
US20170360882A1 (en) Composition for preventing, improving or treating psoriasis comprising immunomodulator and glucosamine
US20030077296A1 (en) Sense enhancing topical gel
WO1994005255A1 (en) Skin moisturizer compositions containing dimethylsulphydryl group releasing agent
EP1048294A2 (en) Use of a nitrate vasodilator alone or in combination with capsaicin for the treatment of pain
Dobes et al. Testosterone propionate in treatment of senile pruritus
CN116059239A (en) Composition containing cannabidiol and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
B Later publication of amended claims

Effective date: 20050207

WWE Wipo information: entry into national phase

Ref document number: 2006502824

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004702515

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004702515

Country of ref document: EP